Deps Patricia D, Nasser Sofia, Guerra Patricia, Simon Marisa, Birshner Rita De Cássia, Rodrigues Laura C
Departamento de Medicina Social, Centro de Ciências da Saúde, Federal University of Espirito Santo, Maruípe, Vitória-ES, Brasil.
Lepr Rev. 2007 Sep;78(3):216-22.
The WHO MDT for leprosy treatment was officially introduced in Brazil in 1991 and comprises three drugs: dapsone, rifampicin and clofazimine. There are few good studies on the frequency of side-effects attributable to MDT in Brazil.
A retrospective and descriptive study carried out in a LCP in Vitória, State of Espirito Santo, Brazil. A specific and detailed protocol about side-effects was prepared and filled in from the patient records.
One hundred ninety four patients' records were analysed looking for side-effects attributable to MDT. Side-effects were attributed to at least one MDT component in 88 (45%) patients and 85 had side-effects due to dapsone, 24 due to rifampicin and 18 due to clofazimine. 185 episodes were identified. The suspected drug was stopped in 47 out of 88 episodes (24% patients); 46 had dapsone stopped, 5 had rifampicin stopped and no-one had clofazimine stopped.
Side-effects attributed to MDT is more frequent than previously described, resulting in interruption of treatment in many patients.
世界卫生组织的麻风病联合化疗方案于1991年在巴西正式推行，该方案包含三种药物：氨苯砜、利福平及氯法齐明。在巴西，针对联合化疗方案副作用发生频率的高质量研究较少。
在巴西圣埃斯皮里图州维多利亚市的一家麻风病防治中心开展了一项回顾性描述性研究。制定了一份关于副作用的详细特定方案，并根据患者记录进行填写。
分析了194例患者的记录，以查找联合化疗方案所致的副作用。88例（45%）患者的副作用归因于至少一种联合化疗药物成分，其中85例因氨苯砜出现副作用，24例因利福平，18例因氯法齐明。共识别出185次不良反应事件。88次事件中有47次（24%的患者）停用了可疑药物；46次停用氨苯砜，5次停用利福平，无人停用氯法齐明。
联合化疗方案所致副作用比之前描述的更为常见，导致许多患者中断治疗。
